Plenary talks {#S1}
=============

Gil Yosipovitch opened the meeting, illuminating his itch journey as the first incumbent of the Jeffrey Bernhard Lecture. This journey began as a resident witnessing the chronic itch suffered by patients with chronic kidney disease culminating leading to a clinical research career via extensive collaborative research. He described the characteristics of different types of chronic itch across the clinical spectrum and is linking these to their neural basis using fMRI.

Earl Carstens from the University of California, Davis asked if itch is a specific sensation distinct from pain. He answered this question affirmatively during the Yasushi Kuraishi Lecture. He demonstrated the existence of subpopulations of specific pruriceptors and central neurons that signal itch He discussed the state-of-the-art regarding neurotransmitters and neuropeptides by demonstrating the specific involvement in itch of subtance P, GRP, glutamate and Nppb. He noted that the development and use of multiple antagonists to target the cognate signaling pathways has great promise with respect to leading to fundamental improvements in the successful treatment of itch.

Clifford Woolf from Boston Children's Hospital described an exciting strategy of reversibly silencing specific subsets of pruritogen- and noxious stimulus-sensitive sensory axons. This was accomplished by using QX-314, a charged sodium-channel blocker derivative of uncharged lidocaine. QX-314 cannot cross membranes because of its positive charge. However, in the presence of channel agonists that open pores, such as capsaicin, QX-313 passes through the pore to reversibly block these same channels. Woolf suggested that targeted silencing of activated sensory fibers provides a new avenue to treating itch.

Basic mechanisms of itch {#S2}
========================

Diana Bautista from University of California, Berkley presented a new model in which thymic stromal lymphopoietin (TSLP) release by keratinocytes, regulated through the ORAI1/NFAT calcium signaling pathway, activates both primary afferent neurons and immune cells to induce inflammatory responses in the skin and airways leading to the "atopic march" seen in atopic patients. The data was subsequently published in Cell.

Sarah Wilson, a postdoctoral fellow in the Bautista lab, discussed the ion channel TRPA1 in a mouse model of chronic itch. Her data suggest that TRPA1 is required for both the transduction of chronic itch signals to the CNS and pathophysiologic skin changes observed in chronic itch.

Xinzhong Dong, from Johns Hopkins discussed Mrgprs, a large family of G-protein-coupled receptors. Mrgprs comprise the receptors for several pruritogens, including chloroquine, the hexapeptide SLIGRL, BAM8-22 and beta-alanine. He demonstrated that Mrgpr-expressing neurons in dorsal root ganglia defined itch-mediating primary sensory neurons with specific projection patters in the skin. Mrgprs may thus serve as novel targets for the treatment of chronic itch.

Sarina B. Elmariah from Massachusetts General Hospital demonstrated that changes in neural innervation occur in an ovalbumin epicutaneous sensitized mouse model of atopic dermatitis. She employs *in vivo* confocal microscopy to visualize peripheral sensory nerves that have been fluorescently labeled genetically. Specific subpopulations of peripheral sensory nerves were highly dynamic throughout the development of dermatitis and resulted in higher innervation density. She also demonstrated that neural blockade during epicutaneous sensitization prevented the neural changes and resulted in reduced scratching behavior. These studies suggest that neural changes may precede immune changes.

Zhou-Feng Chen from Washington University demonstrated that activation of the BRAF pathway in Nav1.8+ neurons of mice causes spontaneous scratching. These mice have increased ectopic expression of gastrin-releasing peptide (GRP) in DRG neurons and the GRP receptor (GRPR) and pERK in the spinal cord. He demonstrated that RAF-MEK-ERK pathway is an upstream regulator of chronic itch. This finding suggests that BFAF inhibitors, already of particular interest in the treatment of certain cancers, including melanoma, may be useful in ameliorating chronic itch.

Mark Hoon from the National Institute of Health gave a lecture on natriuretic polypeptide B (NppB). He demonstrated that NppB knock out mice exhibit significant reduction in scratching bouts in response to injection of different pruritogens while they express normal behavioral responses to thermal and painful stimuli. His work indicated that NppB induced itch requires GRP while GRP induced itch does not require NppB. NppB is thus a functioning upstream of GRP. He concluded that the NppB receptor and GRP are co-expressed in dorsal horn neurons and that NppB is an essential transmitter and mediator of itch at the level of the spinal cord.

Sarah Ross from the University of Pittsburgh presented her work on spinal B5-I interneurons which function to inhibit itch by releasing dynorphin, an endogenous kappa opioid agonist. She demonstrated that spinal modulation of kappa tone bi-directionally modulates itch. These findings provide a mechanism by which kappa opioid agonists may selectively inhibit itch.

Henning Holle from the University of Hull presented his study on the mechanism of contagious itch and demonstrated neuroimaging and behavioral evidence for insular-mediated sharing of affect as the mechanism underlying contagious itch.

Herman O. Handwerker from the Institute of Physiology, Erlangen, presented his work on the functional connectivity of cerebral networks involving cortical somatosensory areas, insular cortices, frontal areas, limbic structures, thalamus and basal ganglia during cerebral processing of experimental itch compared to pain. He reported a higher functional connectivity during pain but regions revealing the highest correlations were similar in both itch and pain states confirming the processing of pain and itch in closely related networks.

Vitaly Napadow from the Martinos Center for Biomedical Imaging presented his study on 14 atopic dermatitis patients and the susceptibility of itch to nocebo and placebo effects. His data suggest that when subjects perceive nocebo induced itch, the prefrontal and striatal circuitry activated by real allergen is also activated.

Andrea Evers from Radboud University Medical Centre presented evidence on the psychophysiological similarities and differences between itch and pain and the implication of therapeutic strategies using placebo mechanisms for chronic itch and pain.

Experimental itch models {#S3}
========================

Robert LaMotte from Yale presented work on chemically elicited biological measurements in mice and how to identify if they relate to itch or other sensory qualities. He has developed an intricate and powerful technology that allows for stimulation of sensory nerves in the skin while directly visualizing them and recording from their cell bodies in the DRG in vivo.

Thiery Olivry, a veterinary dermatology researcher from North Carolina State University demonstrated that atopic dermatitis in dogs closely mimics atopic dermatitis in people. He discussed this large animal model and demonstrated that canines sensitized to allergens provide a powerful model of atopic dermatitis and thus can be used as a proxy for the human condition.

Clinical aspects {#S4}
================

The burden itch was a prominent feature of the meeting. Jacek C. Szepietowski from Wroclaw Medical University, and Thomas Mettang from the German Clinic for Diagnostics, Wiesbaden, suggested the establishment of a new working group of clinicians and scientists for the study of uremic pruritus. Despite the high prevalence of itch in chronic kidney disease, uremic pruritus remains an unresolved problem and its contribution to patient suffering continues to be under appreciated.

Suephy Chen from Emory University reviewed the prevalence of itch and discussed the methodology to measure the burden of itch. Florence Dalgard from University of Oslow, presented the results of her study on patients from dermatology clinics in 13 European countries to assess the burden of itch. She reported that itch had a large impact on the quality of life of affected patients and they were more depressed (13% vs 5%) and experienced more anxiety (21% vs 12%) compared to controls.

David Roblin from Creabilis, a biotechnology start-up, presented a study on 160 psoriasis patients. 97.5% of the patients had itch. Itch in psoriasis is underappreciated and despite the negative effect of itch on the quality of life of psoriasis patients, there are no available therapeutics that target this aspect of the condition.

Cholestatic itch was also discussed extensively, and mouse models are being developed. Nora Bergasa from the Metropolitan Hospital Center, New York, reviewed the itch of cholestasis and discussed the relevance of proposed mechanisms of cholestatic itch. These mechanisms included central opioidergic tone, GRP, the bile acid receptor TGR5 and autotaxin activity. Majedeline Belghiti from Miguel Hernandez University discussed the role of mesenteric mast cell degranulation, TRPV1 and PAR2 in a bile duct ligated rat model of liver disease.

Leigh Nattkemper from Temple University presented her study on the peripheral role of IL-31 in cutaneous T-cell lymphoma patients. IL-31 levels are elevated in epidermal nerve fibers and at the dermopepidermal junction of these patients and correlate with the severity of itch in these patients. Targeting IL-31 with monoclonal antibodies is an active area of investigation and we await preliminary clinical studies in this area.

Itch treatments {#S5}
===============

Sonja Ständer from University Hospital, Münster presented an update on the antipruritic effects of aprepitant, a neurokinin-1 receptor (NK1R) antagonist. She reported significant itch reduction in 62 patients treated with aprepitant with pruritus of various origins. Aprepitant therapy is associated with a decreased number of CD5, CD25 and IL-17 positive T-lymphocytes in skin biopsies.

Charley Merrill from Mitsubishi Tanabe Pharma presented the ongoing investigations on nalfurafine, a centrally active kappa opioid agonist, for the treatment of uremic itch in subjects with chronic kidney disease receiving hemodialysis. This drug is approved for clinical use in Japan and is in ongoing trials in the United States and Europe.

Contrasting findings were set up when Mitsutoshi Tominaga from Juntendo University, in Chiba noted that H4 antagonists were not effective in a mouse model of atopic dermatitis while Robin Thurmond from Janssen Research & Development, San Diego, presented data that H4R antagonism was helpful in treating itch in human atopic dermatitis. He discussed JNJ-39758979, a potent oral H4R antagonist. While clinically effective, off-target effects prevented further development of this specific compound but that the antagonists of a different class should be effective.

Awards {#S6}
======

IFSI's Clinical Research award was given to Henning Holle for his work on auditory modulation of itch. The Basic Research award was provided to Adam Kardon in the laboratory of Sarah Ross for his work demonstrating that dynorphin acts as a neuromodulator to inhibit itch in the spinal cord, thus providing a mechanism by which κ-opioid agonists reduce the sensation of itch. The Handwerker Prize was awarded jointly to Sarah Wilson and Lydia The in the Bautista lab for their laboratory's studies on TSLP.

Summary {#S7}
=======

All aspects of the field of itch, from basic science to quality of life to therapeutics are moving rapidly. Attendees are already looking forward to the next congress, in Nara, Japan in the fall of 2015.
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BAM8-22

:   Bovine adrenal medulla peptide 8-22

CNS

:   central nervous system

CD as in CD5 and CD25

:   cluster of differentiation

DRG

:   dorsal root ganglion

fMRI

:   functional magnetic resonance imaging

GRP

:   gastrin releasing peptide

GRPR

:   gastrin releasing peptide receptor

H4R

:   histamine 4 receptor

IL as in IL-17

:   interleukin

IFSI

:   International Forum for the Study of Itch

Mrgpr

:   Mas-related G-protein coupled receptor

NppB

:   natriuretic polypeptide B

NK1R

:   neurokinin-1 receptor

perk

:   phosphorylated extracellular signal-related kinase

PAR2

:   protease-activated receptor-2

TSLP

:   thymic stromal lymphopoietin

TRPA1

:   transient receptor potential channel A1

TRPV1

:   transient receptor potential channel V1

NaV1.8

:   voltage-gated sodium channel 1.8
